We are pleased to announce that the PARITY trial was recently awarded the Canadian Cancer Society Research Institute’s (CCSRI) Innovation to Impact Grant to support the further development of the successful findings of the PARITY pilot study based on the goals originally explored through the CCSRI Innovation Grant. This application round was highly competitive, with only 3 of 19 applications having been approved – a 16% success rate! The PARITY trial was funded to its full panel recommended amounts and no administrative decrements were applied. Funds committed to this competition have been made possible by the significant efforts of the Canadian Cancer Society volunteers and donors across the country, for which the PARITY team is tremendously grateful.
Thank you to all the PARITY co-investigators and collaborators who contributed letters of support for this funding application! We look forward to continuing the definitive phase of the trial with this CCSRI funding.
Grant: Canadian Cancer Society Research Institute Innovation to Impact Grant
Title: Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A multi-center international randomized controlled trial
Grant Period: 01/02/2015 to 31/01/2018
Principal Investigators: Michelle Ghert and Mohit Bhandari
Co-Investigators and Collaborators: M Anderson, T Balach, A Baptista, T Beckinsale, E Carmody, P Clarkson, M Clayer, J Cummings, B Deheshi, Y Doung, P Ferguson, M Galli Serra, M Gebhardt, D Geller, M Goodman, Y Gortzak, R Grimer, G Guyatt, J Healey, W Hettwer, G Holt, M Isler, B Miller, S Mottard, L Nystrom, T O’Shea, A Puri, RL Randall, N Reimer, J Schwab, L Thabane, R Turcotte, K Weiss, J Werier, J Wunder, J Abraham, R Avedian, T Damron, N Dion, J Hayden, P Jutte, C Kelly, SA Khan, S Puloski, T Scharschmidt, PDS Dijkstra
